Key statistics dashboard for iBio, Inc. (IBIO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Stock Data
| Price | $1.18 |
| Market Cap | $19M |
| Beta | 1.36 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.66 |
| Price / Book | 1.44 |
| P/S | 187.89 |
| P/FCF | -0.79 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -32991.00% |
| EBITDA Margin | -32345.00% |
| Operating Margin | -35141.00% |
| Net Margin | -33044.00% |
Financial Health
| Current Ratio | 7.85 |
| Quick Ratio | 7.85 |
| Cash Ratio | 4.80 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.22% |
| Interest Coverage | -663.04 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -21.93 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.82 |
| Cash per share | 0.85 |
| FCF per share | -0.23 |
| Tangible Book Value per share | 0.81 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.75 |
Related companies: ANTX · BOLD · CVKD · INTS · ITRM · KLTO · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IBIO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks